Visual impairment

Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million

Retrieved on: 
Tuesday, April 2, 2024
Disease, Macular edema, NIU, Paratriathlon, Arm, Rule, Safety, Risk, Webcast, Inflammation, Patient, NEPTUNE, EDT, Master of Science, Haze, Prednisone, Visual acuity, Therapy, Sumitomo Pharma, Calendar, Share repurchase, JAK, Visual impairment, Physician, Hand, Pediatrics, Pharmaceutical industry

We are also pleased to announce our authorized share repurchase program, and our agreed repurchase of all shares owned by Sumitomo Pharma.

Key Points: 
  • We are also pleased to announce our authorized share repurchase program, and our agreed repurchase of all shares owned by Sumitomo Pharma.
  • The NEPTUNE study enrolled 26 subjects with active NIU who were randomized 2:1 to brepocitinib 45 mg once daily or brepocitinib 15 mg once daily.
  • All week 24 secondary efficacy endpoints, including haze grades, visual acuity, and macular thickness, were also positive and dose responsive.
  • The presentation and webcast details are also available under “Events & Presentations” in the Investors section of the Roivant website at https://investor.roivant.com/news-events/events.

OPTIC 2000 & AUSTRALIEGAD LAUNCHED AN ORIGINAL CHALLENGE AT THE GAMERS ASSEMBLY TO RAISE PUBLIC AWARENESS OF VISUAL IMPAIRMENT

Retrieved on: 
Friday, April 5, 2024
Glaucoma, Partnership, Shoe, Macular degeneration, OPTIC, Visual impairment, Challenger, Artha

Optic 2000 is committed to supporting the development of technological innovation to help visually impaired people live independently.

Key Points: 
  • Optic 2000 is committed to supporting the development of technological innovation to help visually impaired people live independently.
  • This weekend, Optic 2000 and Artha launched the "Optic 2000 Challenger" challenge with Salim Ejnaïni, the first visually impaired player equipped with an Artha belt, taking on able-bodied players on the famous Trackmania game.
  • This major event was also an opportunity to raise public awareness of visual impairment and the risks of overexposure to screens.
  • The public could also enjoy an inclusive experience with a workshop designed to raise awareness of visual impairment: by wearing special glasses simulating visual problems (macular degeneration, glaucoma, etc.

OPTIC 2000 & AUSTRALIEGAD LAUNCHED AN ORIGINAL CHALLENGE AT THE GAMERS ASSEMBLY TO RAISE PUBLIC AWARENESS OF VISUAL IMPAIRMENT

Retrieved on: 
Friday, April 5, 2024
Glaucoma, Partnership, Shoe, Macular degeneration, OPTIC, Visual impairment, Challenger, Artha

Optic 2000 is committed to supporting the development of technological innovation to help visually impaired people live independently.

Key Points: 
  • Optic 2000 is committed to supporting the development of technological innovation to help visually impaired people live independently.
  • This weekend, Optic 2000 and Artha launched the "Optic 2000 Challenger" challenge with Salim Ejnaïni, the first visually impaired player equipped with an Artha belt, taking on able-bodied players on the famous Trackmania game.
  • This major event was also an opportunity to raise public awareness of visual impairment and the risks of overexposure to screens.
  • The public could also enjoy an inclusive experience with a workshop designed to raise awareness of visual impairment: by wearing special glasses simulating visual problems (macular degeneration, glaucoma, etc.

Orphan designation: idebenone Treatment of Leber's hereditary optic neuropathy, 16/02/2007 Positive

Retrieved on: 
Tuesday, April 9, 2024
Eurostat, Diagnosis, Civil service commission, Leber's hereditary optic neuropathy, Prevalence, Cell, Patient, Committee, Knowledge, Seriousness, Mitochondrion, Regulation, EMA, IRIS, Adolescence, LHON, European, COMP, Oxygen, Safety, European Commission, Marketing, Visual impairment, Medicine, Pharmaceutical industry

Orphan designation: idebenone Treatment of Leber's hereditary optic neuropathy, 16/02/2007 Positive

Key Points: 


Orphan designation: idebenone Treatment of Leber's hereditary optic neuropathy, 16/02/2007 Positive

BlueRock Therapeutics and Foundation Fighting Blindness announce collaboration to expand the Uni-Rare natural history study of patients living with inherited retinal diseases

Retrieved on: 
Monday, March 25, 2024
Retina, Research, Gene, Development, IRD, Leber congenital amaurosis, Retinitis pigmentosa, Paratriathlon, Patient, Bayer, Foundation Fighting Blindness, Visual impairment, University, Wilfrid Sellars, Senior, IND, Therapy, IPSC, Usher syndrome, B cell, Pharmaceutical industry

The new cohort will include patients living with IRDs caused by mutations in multiple genes.

Key Points: 
  • The new cohort will include patients living with IRDs caused by mutations in multiple genes.
  • “BlueRock is developing a pipeline of cell therapies that we believe has great potential for restoring vision in people living with blindness caused by retinal disease,” said Ahmed Enayetallah, Senior Vice President and Head of Development for BlueRock Therapeutics.
  • Primary photoreceptor diseases are a subgroup of inherited retinal diseases that includes retinitis pigmentosa and cone- rod dystrophies.
  • OpCT-001 aims to restore vision loss caused by these diseases by replacing degenerated tissue in the retina with functional cells.

Tilak Healthcare Strengthens Its Leadership Team

Retrieved on: 
Tuesday, March 19, 2024
Biotechnology, Human Resources, Optical, Finance, Health, Health Technology, Professional Services, Other Health, Retina, Social Security, Conditional sentence, HEC Paris, Euronext Growth, CFO, Partnership, Knowledge, Health care, Information, University, Prescription, Head, Visual impairment, Laboratory, ParisTech, Drug, Alcon, Social, Genomics, Pharmacy, Directorate, Multimedia, Ministry, Doctorate

Tilak Healthcare, a leading company in digital health for the monitoring of chronic eye diseases, announces the appointment of three experts to support the leadership team, currently composed of Edouard Gasser (CEO & co-founder), Philip Bouchet (Chief Operating and Product Officer), and Dr. Bénigne Mathieu (Chief Business Officer).

Key Points: 
  • Tilak Healthcare, a leading company in digital health for the monitoring of chronic eye diseases, announces the appointment of three experts to support the leadership team, currently composed of Edouard Gasser (CEO & co-founder), Philip Bouchet (Chief Operating and Product Officer), and Dr. Bénigne Mathieu (Chief Business Officer).
  • For Benoît Gueugnon, CFO: "I would like to thank the management team as well as the investors of Tilak Healthcare (iBionext, Elaia, Swen Capital, Matmut, Caphorn, and Laboratoires Théa).
  • For Dr. Patricia Zilliox: "I am impressed by Tilak Healthcare's journey, establishing itself as a leader in digital health in ophthalmology.
  • Undoubtedly, these achievements and the quality of the team are undeniable assets for approaching the American market."

RG6501 (OpRegen®) Phase 1/2a Clinical Study 24 Month Results to Be Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit

Retrieved on: 
Wednesday, March 13, 2024
Stem Cells, Biotechnology, Health, Philanthropy, Pharmaceutical, Optical, Research, Genetics, Foundation, Science, Clinical Trials, Geographic atrophy, Patient, Visual impairment, Doctor of Philosophy, MD, Hyatt Regency Seattle, Therapy, RPE, AMD, Cell

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that 24 month results from patients enrolled in a Phase 1/2a clinical study (ClinicalTrials.gov Identifier: NCT02286089 ) of RG6501 ( OpRegen ) in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD), will be presented at the 2024 Retinal Cell & Gene Therapy Innovation Summit .

Key Points: 
  • Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that 24 month results from patients enrolled in a Phase 1/2a clinical study (ClinicalTrials.gov Identifier: NCT02286089 ) of RG6501 ( OpRegen ) in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD), will be presented at the 2024 Retinal Cell & Gene Therapy Innovation Summit .
  • The meeting will be held May 3, 2024, at the Hyatt Regency Seattle, and is jointly organized by the Foundation Fighting Blindness and the Oregon Health & Science University Casey Eye Institute .
  • The presentation, “OpRegen® Retinal Pigment Epithelium (RPE) Cell Therapy for Patients with Geographic Atrophy (GA): Month 24 Results from the Phase 1/2a Trial,” will include anatomical and functional data from long-term follow-up in 10 of 12 patients and will be presented by David Telander, MD, PhD , Retinal Consultants Medical Group, on behalf of Roche and Genentech , a member of the Roche Group.

SetPoint Medical Receives FDA Breakthrough Device Designation for its Neuroimmune Modulation Platform for the Treatment of Multiple Sclerosis

Retrieved on: 
Wednesday, March 13, 2024
Medical Devices, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Vagus nerve, Neurology, Brain, Rheumatoid arthritis, Communication, Multiple sclerosis, Patient, Myelin, Remyelination, Neck, Axon, Clinical trial, Johns Hopkins University, Pain, Nerve, Fatigue, Set, FDA, Visual impairment, RRMS, Food, Pharmaceutical industry

SetPoint Medical , a clinical-stage healthcare company dedicated to patients with chronic autoimmune diseases, announced that it has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for the use of its novel neuroimmune modulation platform for people living with relapsing-remitting multiple sclerosis (RRMS).

Key Points: 
  • SetPoint Medical , a clinical-stage healthcare company dedicated to patients with chronic autoimmune diseases, announced that it has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for the use of its novel neuroimmune modulation platform for people living with relapsing-remitting multiple sclerosis (RRMS).
  • Breakthrough Device Designation will enable interactive communication and priority regulatory review with the FDA, and support reimbursement and patient access upon FDA approval of SetPoint’s technology.
  • This Breakthrough Device Designation is based on evidence demonstrating that SetPoint's treatment has the potential to reduce demyelination and promote remyelination.
  • In 2020, the FDA also granted Breakthrough Device Designation to SetPoint's device for the treatment of rheumatoid arthritis (RA).

Prevent Blindness Provides Free Resources as Part of April's Women's Eye Health and Safety Month to Educate Women on Necessary Steps to Help Save Sight

Retrieved on: 
Wednesday, March 27, 2024
Orbis, IOP, Pigment, Glaucoma, Le Bonheur Children's Hospital, Social media, Pressure, Visual impairment, Contact, Paratriathlon, Intraocular pressure, AAO, Policy, Orbis International, Hormone, Diabetes, Risk, Mental health, Delta Gamma, NIH, Eyelid, Prevalence, Eye, Associate, Safety, Cataract, Menopause, University, Pregnancy, Hospital, Melasma, Public health, Lactation, Puberty, American Academy, Lens, Telecanthus, Eye disease, Graves' ophthalmopathy, Bangladesh Technical Education Board, Dry eye syndrome, Pediatrics, Birth control

CHICAGO, March 27, 2024 /PRNewswire-PRWeb/ -- Prevent Blindness, the nation's leading nonprofit eye health organization, has declared April as Women's Eye Health and Safety Month. According to Orbis International, globally there are 112 million more women than men living with vision loss, including blindness. Prevent Blindness is offering free resources, including fact sheets, shareable social media graphics, educational videos and web pages, on a range of eye health issues that predominantly affect women.

Key Points: 
  • CHICAGO, March 27, 2024 /PRNewswire-PRWeb/ -- Prevent Blindness , the nation's leading nonprofit eye health organization, has declared April as Women's Eye Health and Safety Month.
  • Prevent Blindness is offering free resources, including fact sheets, shareable social media graphics, educational videos and web pages, on a range of eye health issues that predominantly affect women.
  • Women have a higher prevalence of age-related macular degeneration, cataract, dry eye, glaucoma, refractive error and thyroid eye disease.
  • For more information on women's eye health topics, including fact sheets on eye diseases and eye safety, please visit PreventBlindness.org.

Glaucoma Research Foundation Releases Informational Audiobook for Glaucoma Patients in Collaboration with Braille Institute of America

Retrieved on: 
Tuesday, March 19, 2024
Glaucoma, Paratriathlon, Patient, SAN, Knowledge, Braille, GRF, Braille Institute of America, MD, Quality of life, Multimedia, Visual impairment

The free glaucoma audiobook narrated by Bianca Beach is available for patients to listen, download, and share.

Key Points: 
  • The free glaucoma audiobook narrated by Bianca Beach is available for patients to listen, download, and share.
  • Narrated by Orange County actress, advocate, and glaucoma patient Bianca Beach, the audiobook project is a collaboration with Braille Institute of America, a nonprofit organization that provides free programs, seminars, and one-on-one instruction for the visually impaired community.
  • The free educational booklet is edited by glaucoma specialists and recommended by eye doctors as a wonderfully understandable introduction to glaucoma."
  • We're always seeking ways to educate patients to help them understand and manage their condition in collaboration with their doctor.